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Background: Antiplatelet therapy, including aspirin (ASA) and clopidogrel, is cornerstone therapy for patients with acute myocardial infarction 
(AMI). The present analysis assessed the readmission rates in patients with AMI who were treated with or without in-hospital dual antiplatelet therapy 
(ASA ± clopidogrel).
Methods: Patients with an index hospitalization for AMI in 2008 and received ASA with or without clopidogrel during hospitalization were selected 
based on in-hospital diagnoses and pharmacy records from over 2800 hospitals in a large US hospital discharge database (MarketScan® Hospital 
Drug Database). Readmission for any reason or recurrent AMI within 30 days and 1 year following discharge for index AMI event was assessed based 
on hospital records. Logistic regression was used to evaluate the relationship between readmission and in-hospital antiplatelet therapy, adjusted for 
patient demographics, comorbidities, AMI type, and coronary revascularization procedure during index hospitalization.
Results: Among 32,970 eligible patients with index AMI (mean age 68 yrs; 60% male), 34% received ASA alone and 66% received ASA + clopidogrel 
during index hospitalization. Patients on ASA + clopidogrel were younger, had more severe AMI, higher rate for dyslipidemia, but lower rates for atrial 
fibrillation, congestive heart failure, hypertension, diabetes, cerebrovascular disease, renal disease, and cancer than patients on ASA alone (all 
p<0.001). Overall, the readmission rate for any reason was 6.8% within 30 days and 30.9% within 1 year; and for recurrent AMI the rate was 1.4% 
within 30 days and 6.5% within 1 year. Compared to patients on ASA alone, patients on ASA + clopidogrel were more likely to have readmission for 
any reason within 1 year (adjusted odds ratio (OR) = 1.21 [95% CI: 1.13, 1.28]), and readmission for recurrent AMI within 30 days (OR = 1.35 [1.06, 
1.70]) and within 1 year (OR = 1.61 [1.42, 1.82]).
Conclusions: Both 30-day and 1-year readmission rates remained high following AMI discharge in patients treated with ASA ± clopidogrel in-
hospital. The dual antiplatelet therapy was not associated with a reduction in readmission rate in our study cohort.
